Search Page

1

Cite

Share

Non-glucose metabolism in cancer cells--is it all in the fat?

Biswas S, Lunec J, Bartlett K. Biswas S, et al. Among authors: lunec j. Cancer Metastasis Rev. 2012 Dec;31(3-4):689-98. doi: 10.1007/s10555-012-9384-6. Cancer Metastasis Rev. 2012. PMID: 22706846 Review.

Cite

Share

2

Cite

Share

The MYCN oncoprotein as a drug development target.

Lu X, Pearson A, Lunec J. Lu X, et al. Among authors: lunec j. Cancer Lett. 2003 Jul 18;197(1-2):125-30. doi: 10.1016/s0304-3835(03)00096-x. Cancer Lett. 2003. PMID: 12880971 Review.

Cite

Share

3

Cite

Share

Genes co-amplified with MYCN in neuroblastoma: silent passengers or co-determinants of phenotype?

Scott D, Elsden J, Pearson A, Lunec J. Scott D, et al. Among authors: lunec j. Cancer Lett. 2003 Jul 18;197(1-2):81-6. doi: 10.1016/s0304-3835(03)00086-7. Cancer Lett. 2003. PMID: 12880964 Review.

Cite

Share

4

Cite

Share

Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma.

Rankin KS, Starkey M, Lunec J, Gerrand CH, Murphy S, Biswas S. Rankin KS, et al. Among authors: lunec j. Pediatr Blood Cancer. 2012 Mar;58(3):327-33. doi: 10.1002/pbc.23341. Epub 2011 Oct 11. Pediatr Blood Cancer. 2012. PMID: 21990244 Review.

Cite

Share

5

Cite

Share

Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells.

Logan IR, McNeill HV, Cook S, Lu X, Lunec J, Robson CN. Logan IR, et al. Among authors: lunec j. Prostate. 2007 Jun 1;67(8):900-6. doi: 10.1002/pros.20568. Prostate. 2007. PMID: 17440969

Cite

Share

6

Cite

Share

Identification and characterisation of STMN4 and ROBO2 gene involvement in neuroblastoma cell differentiation.

Sung PJ, Boulos N, Tilby MJ, Andrews WD, Newbold RF, Tweddle DA, Lunec J. Sung PJ, et al. Among authors: lunec j. Cancer Lett. 2013 Jan 1;328(1):168-75. doi: 10.1016/j.canlet.2012.08.015. Epub 2012 Aug 17. Cancer Lett. 2013. PMID: 22906418

Cite

Share

7

Cite

Share

Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse.

Carr J, Bell E, Pearson AD, Kees UR, Beris H, Lunec J, Tweddle DA. Carr J, et al. Among authors: lunec j. Cancer Res. 2006 Feb 15;66(4):2138-45. doi: 10.1158/0008-5472.CAN-05-2623. Cancer Res. 2006. PMID: 16489014

Cite

Share

8

Cite

Share

The p53 pathway and its inactivation in neuroblastoma.

Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C, Lunec J. Tweddle DA, et al. Among authors: lunec j. Cancer Lett. 2003 Jul 18;197(1-2):93-8. doi: 10.1016/s0304-3835(03)00088-0. Cancer Lett. 2003. PMID: 12880966 Review.

Cite

Share

9

Cite

Share

Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.

Wu CE, Esfandiari A, Ho YH, Wang N, Mahdi AK, Aptullahoglu E, Lovat P, Lunec J. Wu CE, et al. Among authors: lunec j. Br J Cancer. 2018 Feb 20;118(4):495-508. doi: 10.1038/bjc.2017.433. Epub 2017 Dec 12. Br J Cancer. 2018. PMID: 29235570 Free PMC article.

Cite

Share

10

Cite

Share

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.

Zanjirband M, Edmondson RJ, Lunec J. Zanjirband M, et al. Among authors: lunec j. Oncotarget. 2016 Jun 28;7(26):40115-40134. doi: 10.18632/oncotarget.9499. Oncotarget. 2016. PMID: 27223080 Free PMC article.

Cite

Share